The fusion of two worlds: Non-coding RNAs and extracellular vesicles - Diagnostic and therapeutic implications (Review)

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 17-27

  Sato Kuwabara, Yukie ^a,b   Melo, Sonia A ^a,c   Soares, Fernando A ^b,d   Calin, George A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Exosomes; Extravesicles; Long non coding RNA; MicroRNAs

Indexed keywords

MICRORNA; UNTRANSLATED RNA;

ANIMAL; DIAGNOSTIC USE; EXOSOME; GENETICS; HUMAN; MOLECULAR DIAGNOSIS; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; EXOSOMES; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; RNA, UNTRANSLATED;

EID: 84917711130     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2712     Document Type: Article

References (140)

1. Mattick JS: Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep 2: 986-991, 2001.
2. Morceau F, Chateauvieux S, Gaigneaux A, Dicato M and Diederich M: Long and short non-coding RNAs as regulators of hematopoietic differentiation. Int J Mol Sci 14: 14744-14770, 2013.
3. Mattick JS and Makunin IV: Non-coding RNA. Hum Mol Genet 15 Spec No 1: R17-R29, 2006.
4. Amaral PP and Mattick JS: Noncoding RNA in development. Mamm Genome 19: 454-492, 2008.
5. Setoyama T, Ling H, Natsugoe S and Calin GA: Non-coding RNAs for medical practice in oncology. Keio J Med 60: 106-113, 2011.
6. Vader P, Breakefield XO and Wood MJA: Extracellular vesicles: emerging targets for cancer therapy. Trends Mol Med 20: 385-393, 2014.
7. Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: insights into functions. Nat Rev Genet 10: 155-159, 2009.
8. Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov 1: 391-407, 2011.
9. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
10. Wightman B, Ha I and Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75: 855-862, 1993.
11. Zhang W, Dahlberg JE and Tam W: MicroRNAs in tumorigenesis: a primer. Am J Pathol 171: 728-738, 2007.
12. Siomi H and Siomi MC: Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell 38: 323-332, 2010.
13. Raisch J, Darfeuille-Michaud A and Nguyen HTT: Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol 19: 2985-2996, 2013.
14. Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865, 2013.
15. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002.
16. Yendamuri S and Calin GA: The role of microRNA in human leukemia: a review. Leukemia 23: 1257-1263, 2009.
17. Balatti V, Pekarky Y, Rizzotto L and Croce CM: miR deregulation in CLL. Adv Exp Med Biol 792: 309-325, 2013.
18. Gordon JEA, Wong JJ-L and Rasko JEJ: MicroRNAs in myeloid malignancies. Br J Haematol 162: 162-176, 2013.
19. Srivastava S, Tsongalis GJ and Kaur P: Recent advances in microRNA-mediated gene regulation in chronic lymphocytic leukemia. Clin Biochem 46: 901-908, 2013.
20. Rossi S, Kopetz S, Davuluri R, Hamilton SR and Calin GA: MicroRNAs, ultraconserved genes and colorectal cancers. Int J Biochem Cell Biol 42: 1291-1297, 2010.
21. Hong L, Han Y, Zhou Y and Nita A: Angiogenesis-related microRNAs in colon cancer. Expert Opin Biol Ther 13: 77-84, 2013.
22. Hutchison J, Cohen Z, Onyeagucha BC, Funk J and Nelson MA: How microRNAs influence both hereditary and inflammatory-mediated colon cancers. Cancer Genet 206: 309-316, 2013.
23. Menéndez P, Villarejo P, Padilla D, Menéndez JM and Rodríguez-Montes JA: Implications of the histological determination of microRNAs in the screening, diagnosis and prognosis of colorectal cancer. J Surg Oncol 108: 70-73, 2013.
24. Ferracin M, Querzoli P, Calin GA and Negrini M: MicroRNAs: toward the clinic for breast cancer patients. Semin Oncol 38: 764-775, 2011.
25. Harquail J, Benzina S and Robichaud GA: MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark 11: 269-280, 2012.
26. Zhang ZJ and Ma SL: miRNAs in breast cancer tumorigenesis (Review). Oncol Rep 27: 903-910, 2012.
27. Mulrane L, McGee SF, Gallagher WM and O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res 73: 6554-6562, 2013.
28. Singh R and Mo Y-Y: Role of microRNAs in breast cancer. Cancer Biol Ther 14: 201-212, 2013.
29. John K, Wu J, Lee B-W and Farah CS: MicroRNAs in head and neck cancer. Int J Dent 2013: 650218, 2013.
30. Nagadia R, Pandit P, Coman WB, Cooper-White J and Punyadeera C: miRNAs in head and neck cancer revisited. Cell Oncol (Dordr) 36: 1-7, 2013.
31. Nohata N, Hanazawa T, Kinoshita T, Okamoto Y and Seki N: MicroRNAs function as tumor suppressors or oncogenes: aberrant expression of microRNAs in head and neck squamous cell carcinoma. Auris Nasus Larynx 40: 143-149, 2013.
32. Tu HF, Lin SC and Chang KW: MicroRNA aberrances in head and neck cancer: pathogenetic and clinical significance. Curr Opin Otolaryngol Head Neck Surg 21: 104-111, 2013.
33. Song JH and Meltzer SJ: MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 143: 35-47.e2, 2012.
34. Wang F, Sun GP, Zou YF, Hao JQ, Zhong F and Ren WJ: MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark 11: 259-267, 2012.
35. Gao M, Yin H and Fei ZW: Clinical application of microRNA in gastric cancer in Eastern Asian area. World J Gastroenterol 19: 2019-2027, 2013.
36. Song S and Ajani JA: The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol 10: 109-118, 2013.
37. K apranov P, Cheng J, Dike S, et al: RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316: 1484-1488, 2007.
38. Okazaki Y, Furuno M, Kasukawa T, et al: Analysis of the mouse transcriptome based on functional annotation of 60, 770 full-length cDNAs. Nature 420: 563-573, 2002.
39. Esteller M: Non-coding RNAs in human disease. Nat Rev Genet 12: 861-874, 2011.
40. Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 31: 4577-4587, 2012.
41. Tang JY, Lee JC, Chang YT, Hou MF, Huang HW, Liaw CC and Chang HW: Long noncoding RNAs-related diseases, cancers, and drugs. Sci World J 2013: 943539, 2013.
42. V an Roosbroeck K, Pollet J and Calin GA: miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn 13: 183-204, 2013.
43. Shi X, Sun M, Liu H, Yao Y and Song Y: Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett 339: 159-166, 2013.
44. Fitzgerald KA and Caffrey DR: Long noncoding RNAs in innate and adaptive immunity. Curr Opin Immunol 26: 140-146, 2014.
45. Jendrzejewski J, He H, Radomska HS, et al: The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci USA 109: 8646-8651, 2012.
46. Fan M, Li X, Jiang W, Huang Y, Li J and Wang Z: A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp Ther Med 5: 1143-1146, 2013.
47. Hessels D and Schalken JA: The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 6: 255-261, 2009.
48. Day JR, Jost M, Reynolds MA, Groskopf J and Rittenhouse H: PCA3: from basic molecular science to the clinical lab. Cancer Lett 301: 1-6, 2011.
49. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D and Bièche I: Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67: 3963-3969, 2007.
50. Iacobucci I, Sazzini M, Garagnani P, et al: A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. Leuk Res 35: 1052-1059, 2011.
51. Cheetham SW, Gruhl F, Mattick JS and Dinger ME: Long noncoding RNAs and the genetics of cancer. Br J Cancer 108: 2419-2425, 2013.
52. Cheng W, Zhang Z and Wang J: Long noncoding RNAs: new players in prostate cancer. Cancer Lett 339: 8-14, 2013.
53. Ji P, Diederichs S, Wang W, et al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22: 8031-8041, 2003.
54. Gutschner T and Diederichs S: The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9: 703-719, 2012.
55. Li CH and Chen Y: Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol 45: 1895-1910, 2013.
56. Martens-Uzunova ES, Olvedy M and Jenster G: Beyond microRNA-novel RNAs derived from small non-coding RNA and their implication in cancer. Cancer Lett 340: 201-211, 2013.
57. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
58. Gilad S, Meiri E, Yogev Y, et al: Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148, 2008.
59. De Planell-Saguer M and Rodicio MC: Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta 699: 134-152, 2011.
60. Ajit SK: Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel) 12: 3359-3369, 2012.
61. Schwarzenbach H, Nishida N, Calin GA and Pantel K: Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11: 145-156, 2014.
62. Lawrie CH, Gal S, Dunlop HM, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675, 2008.
63. Luo X, Stock C, Burwinkel B and Brenner H: Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One 8: e62880, 2013.
64. Wang J, Huang S-K, Zhao M, et al: Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One 9: e87451, 2014.
65. K omatsu S, Ichikawa D, Takeshita H, et al: Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 105: 104-111, 2011.
66. Wu C, Wang C, Guan X, et al: Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One 9: e92292, 2014.
67. Chan M, Liaw CS, Ji SM, et al: Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 19: 4477-4487, 2013.
68. Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB, Robinson BG and Soon PS: MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC Cancer 14: 200, 2014.
69. Tsujiura M, Ichikawa D, Komatsu S, et al: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 102: 1174-1179, 2010.
70. Zhu C, Ren C, Han J, et al: A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer 110: 2291-2299, 2014.
71. Zheng H, Liu JY, Song FJ and Chen KX: Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med 10: 123-130, 2013.
72. Shapira I, Oswald M, Lovecchio J, et al: Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer 110: 976-983, 2014.
73. K osaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087-2092, 2010.
74. Ahmed KA and Xiang J: Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med 15: 1458-1473, 2011.
75. Ogorevc E, Kralj-Iglic V and Veranic P: The role of extracellular vesicles in phenotypic cancer transformation. Radiol Oncol 47: 197-205, 2013.
76. Lee TH, D'Asti E, Magnus N, Al-Nedawi K, Meehan B and Rak J: Microvesicles as mediators of intercellular communication in cancer - the emerging science of cellular 'debris'. Semin Immunopathol 33: 455-467, 2011.
77. Zhang HG and Grizzle WE: Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 184: 28-41, 2014.
78. Choi DS, Kim DK, Kim YK and Gho YS: Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics 13: 1554-1571, 2013.
79. El Andaloussi S, Mäger I, Breakefield XO and Wood MJA: Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12: 347-357, 2013.
80. Raposo G and Stoorvogel W: Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200: 373-383, 2013.
81. V an der Pol E, Böing AN, Harrison P, Sturk A and Nieuwland R: Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 64: 676-705, 2012.
82. Simpson RJ, Jensen SS and Lim JWE: Proteomic profiling of exosomes: current perspectives. Proteomics 8: 4083-4099, 2008.
83. Nazarenko I, Rupp A-K and Altevogt P: Exosomes as a potential tool for a specific delivery of functional molecules. Methods Mol Biol 1049: 495-511, 2013.
84. Principe S, Hui ABY, Bruce J, Sinha A, Liu FF and Kislinger T: Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery. Proteomics 13: 1608-1623, 2013.
85. Akers JC, Gonda D, Kim R, Carter BS and Chen CC: Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus- like vesicles, and apoptotic bodies. J Neurooncol 113: 1-11, 2013.
86. Mathivanan S, Ji H and Simpson RJ: Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73: 1907-1920, 2010.
87. K osaka N, Yoshioka Y, Hagiwara K, Tominaga N, Katsuda T and Ochiya T: Trash or treasure: extracellular microRNAs and cell-to-cell communication. Front Genet 4: 173, 2013.
88. Martins VR, Dias MS and Hainaut P: Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol 25: 66-75, 2013.
89. K ahlert C, Melo SA, Protopopov A, et al: Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 289: 3869-3875, 2014.
90. Fang DY, King HW, Li JY and Gleadle JM: Exosomes and the kidney: blaming the messenger. Nephrology (Carlton) 18: 1-10, 2013.
91. Gajos-Michniewicz A, Duechler M and Czyz M: MiRNA in melanoma-derived exosomes. Cancer Lett 347: 29-37, 2014.
92. Peinado H, Lavotshkin S and Lyden D: The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21: 139-146, 2011.
93. Théry C, Amigorena S, Raposo G and Clayton A: Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3: Unit 3.22, 2006.
94. Lässer C: Identification and analysis of circulating exosomal microRNA in human body fluids. Methods Mol Biol 1024: 109-128, 2013.
95. Gonda DD, Akers JC, Kim R, Kalkanis SN, Hochberg FH, Chen CC and Carter BS: Neuro-oncologic applications of exosomes, microvesicles, and other nano-sized extracellular particles. Neurosurgery 72: 501-510, 2013.
96. Lässer C, Eldh M and Lötvall J: Isolation and characterization of RNA-containing exosomes. J Vis Exp: e3037, 2012.
97. V aladi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659, 2007.
98. Jenjaroenpun P, Kremenska Y, Nair VM, Kremenskoy M, Joseph B and Kurochkin IV: Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing. Peer J 1: e201, 2013.
99. K ruger S, Abd Elmageed ZY, Hawke DH, et al: Molecular characterization of exosome-like vesicles from breast cancer cells. BMC Cancer 14: 44, 2014.
100. Feng DQ, Huang B, Li J, et al: Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. Asian Pac J Cancer Prev 14: 7501-7508, 2013.
101. Xiao D, Ohlendorf J, Chen Y, et al: Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS ONE 7: e46874, 2012.
102. Rappa G, Mercapide J, Anzanello F, Pope RM and Lorico A: Biochemical and biological characterization of exosomes containing prominin-1/CD133. Mol Cancer 12: 62, 2013.
103. Hessvik NP, Phuyal S, Brech A, Sandvig K and Llorente A: Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta 1819: 1154-1163, 2012.
104. K obayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD and Rice GE: Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med 12: 4, 2014.
105. Ohshima K, Inoue K, Fujiwara A, et al: Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 5: e13247, 2010.
106. Zöller M: Pancreatic cancer diagnosis by free and exosomal miRNA. World J Gastrointest Pathophysiol 4: 74-90, 2013.
107. Chiba M, Kimura M and Asari S: Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. Oncol Rep 28: 1551-1558, 2012.
108. Yang M, Chen J, Su F, et al: Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 10: 117, 2011.
109. Umezu T, Ohyashiki K, Kuroda M and Ohyashiki JH: Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 32: 2747-2755, 2013.
110. K osaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F and Ochiya T: Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem 287: 1397-1405, 2012.
111. Roccaro AM, Sacco A, Maiso P, et al: BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 123: 1542-1555, 2013.
112. V alencia K, Luis-Ravelo D, Bovy N, et al: miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol Oncol 8: 689-703, 2014.
113. Zhou W, Fong MY, Min Y, et al: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25: 501-515, 2014.
114. Chen W, Zhong S, Ji M, et al: MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biol 35: 2883-2892, 2014.
115. Xiao X, Yu S, Li S, et al: Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin. PLoS One 9: e89534, 2014.
116. K ing HW, Michael MZ and Gleadle JM: Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 12: 421, 2012.
117. Tadokoro H, Umezu T, Ohyashiki K, Hirano T and Ohyashiki JH: Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem 288: 34343-34351, 2013.
118. Skog J, Würdinger T, van Rijn S, et al: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476, 2008.
119. Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21, 2008.
120. Tanaka Y, Kamohara H, Kinoshita K, et al: Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 119: 1159-1167, 2013.
121. Ogata-Kawata H, Izumiya M, Kurioka D, et al: Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 9: e92921, 2014.
122. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42-46, 2009.
123. Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN and Pass HI: microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 8: 1156-1162, 2013.
124. Rodríguez M, Silva J, López-Alfonso A, et al: Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer: Apr 25, 2014 (Epub ahead of print).
125. Li L, Masica D, Ishida M, et al: Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology: Feb 4, 2014 (Epub ahead of print).
126. Liu J, Sun H, Wang X, Yu Q, Li S, Yu X and Gong W: Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. Int J Mol Sci 15: 758-773, 2014.
127. Kogure T, Yan IK, Lin W-L and Patel T: Extracellular vesiclemediated transfer of a novel long noncoding RNA TUC339: A mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer 4: 261-272, 2013.
128. Takahashi K, Yan IK, Haga H and Patel T: Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J Cell Sci 127: 1585-1594, 2014.
129. Arita T, Ichikawa D, Konishi H, et al: Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res 33: 3185-3193, 2013.
130. Ren S, Wang F, Shen J, et al: Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 49: 2949-2959, 2013.
131. Panzitt K, Tschernatsch MMO, Guelly C, et al: Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132: 330-342, 2007.
132. Xie H, Ma H and Zhou D: Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int 2013: 136106, 2013.
133. Isin M, Ozgur E, Cetin G, Erten N, Aktan M, Gezer U and Dalay N: Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta 431: 255-259, 2014.
134. Lässer C: Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors. Expert Opin Biol Ther 12 (Suppl 1): S189-S197, 2012.
135. Lee Y, El Andaloussi S and Wood MJA: Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 21: R125-R134, 2012.
136. Kosaka N, Takeshita F, Yoshioka Y, Hagiwara K, Katsuda T, Ono M and Ochiya T: Exosomal tumor-suppressive microRNAs as novel cancer therapy: 'exocure' is another choice for cancer treatment. Adv Drug Deliv Rev 65: 376-382, 2013.
137. Ohno S, Takanashi M, Sudo K, et al: Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 21: 185-191, 2013.
138. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S and Wood MJA: Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29: 341-345, 2011.
139. Wahlgren J, De L Karlson T, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P and Valadi H: Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 40: e130, 2012.
140. Bronisz A, Wang Y, Nowicki MO, et al: Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res 74: 738-750, 2014.